Table 1 Patients characteristics and transplant outcome.
From: Poems syndrome: consolidation with autologous stem cell transplantation
Parameter | Value | ||
|---|---|---|---|
Age at diagnosis (years), median (range) | 42 (26–59) | ||
Sex (M:F) | 16:3 | ||
ECOG PS | N = 19 | ||
2 | 5 (26.3%) | ||
3 | 7 (36.8%) | ||
4 | 7 (36.8%) | ||
Interval from diagnosis to transplant median (range) | 11.9 (4.9-75.6) | ||
POEMS syndrome marker | N (%) | ||
Polyneuropathy | 19 (100) | ||
Monoclonal Plasmacytosis | 18 (94.7) | ||
Castleman Disease | 6 (31.5) | ||
*Hyaline vascular | 5/6 | ||
*Plasma cell variant | 1/6 | ||
#multicentric | 5/6 | ||
Sclerotic bone lesion | 12 (63.1) | ||
Organomegaly | 9 (47.3) | ||
Lymphadenopathy | 9 (47.3) | ||
Skin Changes | 12 (63.1) | ||
Endocrinopathy | 10 (52.6) | ||
Gonadal dysfunction | 9 (47.3) | ||
Thyroid dysfunction | 5 (26.3) | ||
Adrenal dysfunction | 5 (26.3) | ||
Gynecomastia | 3 (15.7) | ||
Extravascular Volume Overload | 11 (57.8) | ||
Papilledema | 7 (36.8) | ||
Clubbing | 4 (21) | ||
Thrombocytosis (>4.5lakhs) | 3 (15.7) | ||
Weight loss >5kg- | 6 (31.5) | ||
Fatigue | 11(57.8) | ||
Ig Characteristic (Heavy & light chain) | |||
IgG Lambda | 8(42.1) | ||
IgG Kappa | 4 (21) | ||
IgG Kappa + Lambda | 1 (5) | ||
Ig A Lambda | 1 (5) | ||
Lambda light chain | 1 (5) | ||
Kappa light chain | 2 (10.5) | ||
Focal | 1 (5) | ||
Negative | 1 (5) | ||
Bone marrow involvement | |||
> =10% | 3 (15.7) | ||
5–9% | 7 (36.8) | ||
< 5% | 9 (47.2) | ||
Induction | |||
Vd | 11 (57.8) | ||
VRd | 4 (21.05) | ||
Rd | 2 (10.5) | ||
RVCd | 1 (5.26) | ||
MP | 1 (5.26 | ||
Response after induction (median 6 cycles) | |||
CHR | 13 (68.4) | ||
PHR | 4 (21.05) | ||
Stable | 2 (10.5) | ||
Stem cell mobilisation: | |||
G-CSF | 13 (68.4%) | ||
G-CSF + Plerixafor | 6 (31.5%) | ||
Median stem cell dose, x 106 CD34 cells/kg | 2.64(1.83-7.05) | ||
High dose Melphalan: | |||
•140 mg/m2 | 11 (57.8%) | ||
•160 mg/m2 | 2(10.5%) | ||
•200 mg/ m2 | 6(31.5%) | ||
Hematological Response (median 6 cycles received) | Post-Induction | Pre -ASCT | Post ASCT- D + 100 |
CR | 13 | 15 | 19(100%) |
PR | 4 | 4 | |
Stable | 4 | 0 | |
Neurological Response | |||
CR | 0 | 0 | 1 |
PR | 16 | 12 | 16 |
SD | 2 | 5 | 2 |
PD | 1 | 0 | 0 |
mRS | |||
1 | 0 | 2 | 3 |
2 | 4 | 4 | 9 |
3 | 12 | 10 | 7 |
4 | 3 | 3 | 0 |
Overall Clinical response | Partial Response | Partial response | |
